Tue Feb 04 15:00:00 UTC 2025: ## Hims & Hers Remains Unfazed by Tirzepatide Shortage Resolution
**New York, NY** – The resolution of the tirzepatide shortage, announced by the FDA in December 2024, has not impacted Hims & Hers Health, Inc. (NYSE:HIMS), according to a recent Seeking Alpha analysis. While the company has never offered compounded tirzepatide treatments, the analyst notes that the shortage’s resolution remains on their radar. The analysis emphasizes that this observation is purely speculative and based on independent analysis, with the author declaring no financial stake in the company. Investors are advised to conduct their own due diligence before making any investment decisions.
First Piper 